Evaluation of the MORENO Score for the Regulation (ESMORTSAB19)

August 13, 2024 updated by: University Hospital, Brest

Evaluation of the MORENO Score for the Regulation of Secondary Transfers to the UAS-SMUR in Brest in Finistère in 2020

The main objective of this work is therefore to evaluate the safety and feasibility of the MORENO score for the regulation of secondary transfers to the SAMU 29 compared to current practices.

Study Overview

Status

Completed

Conditions

Detailed Description

Today, there is an increase in the number of secondary transfers and paramedical transport between the different hospitals in a territory. They have been promoted by the SFMU (French Society of Emergency Medicine) since 2012.

The sharp increase in the number of calls for SAMU regulation means that decisions must be made quickly and safely regarding transport requiring or not requiring a medical presence. The development of a decision support tool for the level of medicalisation of a transfer therefore seems necessary. However, there is currently no recommendation in France.

The MORENO score has already been used in a hospital in the Var, as well as in Spain and Greece. Prior validation of this score in our health territory is essential before setting up an operational procedure. Using a list of simple clinical items, this score enables us to assess whether or not it is necessary to medicalise a transfer.

Study Type

Observational

Enrollment (Actual)

1500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Brest, France, 29609
        • CHU Brest

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

All adult patients having benefited from a transfer

Description

Inclusion Criteria:

  • All adult patients having benefited from a transfer regulated by the SAMU 29 of adult patients on the Finistère territory over a predefined period of time

Exclusion Criteria:

  • Pediatric patient transfers
  • Maritime transfers
  • Transfers for which the collected information does not allow to establish the MORENO score.
  • Patients under judicial protection (guardianship, curatorship,..)
  • Opposition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of the concordance of the MORENO score for the regulation of secondary transfers at SAMU 29 and our current practices
Time Frame: 1 year
Rate of agreement between our practices and the MORENO score strategy.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Brest

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2020

Primary Completion (Actual)

June 30, 2021

Study Completion (Actual)

June 30, 2021

Study Registration Dates

First Submitted

August 13, 2024

First Submitted That Met QC Criteria

August 13, 2024

First Posted (Actual)

August 15, 2024

Study Record Updates

Last Update Posted (Actual)

August 15, 2024

Last Update Submitted That Met QC Criteria

August 13, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 29BRC20.0075

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All collected data that underlie results in a publication

IPD Sharing Time Frame

Data will be available beginning three years and ending fifteen years following the final study report completion

IPD Sharing Access Criteria

Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe